机构：[1]Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan四川省人民医院[2]Institute for Hospital Management of Tsinghua University, Shenzhen, China深圳市康宁医院深圳医学信息中心[3]Sichuan University, Chengdu, China
Providing universal access to high-cost medications like anticancer drugs is not an easy feat. Although basic medical insurance has covered over 95% of China's population since 2012, reimbursement for high-priced medicines is limited. In 2015, the Chinese government proposed establishing an open and transparent price negotiation mechanism for some patented and expensive drugs, where oncology was among the prioritized areas. In 2016, three drugs (gefitinib, icotinib, and tenofovir disoprox) underwent negotiation with the government, eventually reducing their prices by over 50% so that they could be prioritized during reimbursement processes. Focusing on anticancer medicines, this study comprehensively summarizes the progress in drug price and national reimbursement negotiation in China. Furthermore, we investigated the changes and development regarding negotiated anticancer medicines from quantity negotiated, classification, indication coverage, utilization, and procurement spending. Our findings could provide a reference for follow-up negotiations and reimbursement policies for high-value anticancer medications in other countries. From 2016 to 2021, 82 anticancer medicines were newly incorporated into the national reimbursement drug list (NRDL) via 6 rounds of negotiation. The majority of these were innovative pharmaceutics (ie, protein kinase inhibitors (28) and monoclonal antibodies (13)). Drug pricing and national reimbursement negotiation led to a marked decrease in prices and a sharp increase in the utilization of negotiated anticancer medicines. Following negotiations, the defined daily doses (DDDs) of innovative anticancer medicines experienced remarkable growth. Their proportion in total anticancer drugs DDDs also increased from 3.4% in 2014 to 20.9% in 2019. However, although drug prices decreased substantially after the negotiations, insurance spending still showed an upward trend owing to the significant increase in utilization. This calls for the government to carefully monitor the rational use of these expensive medicines and explore innovative payment models.
基金：
This
work was supported by the China and Key Research Project of
Sichuan Science and Technology Department [grant number
2016SZ0077].
语种：
外文
高被引：
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|4 区医学
小类|4 区卫生保健与服务4 区卫生政策与服务
最新[2023]版：
大类|4 区医学
小类|4 区卫生保健与服务4 区卫生政策与服务
JCR分区：
出版当年[2023]版：
Q3HEALTH CARE SCIENCES & SERVICESQ3HEALTH POLICY & SERVICES
最新[2023]版：
Q3HEALTH CARE SCIENCES & SERVICESQ3HEALTH POLICY & SERVICES
第一作者机构：[1]Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan
通讯作者：
通讯机构：[1]Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan[*1]University of Electronic Science and Technology of China Sichuan Provincial People’s Hospital, 32 West Second Section First Ring Road, Chengdu, Sichuan 610072, China.
推荐引用方式(GB/T 7714)：
Mingge Xia,Jingyu Wen,Qi Liu,et al.Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China[J].INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING.2023,60:doi:10.1177/00469580231170729.
APA：
Mingge Xia,Jingyu Wen,Qi Liu,Zhe Zheng&Qing Ran.(2023).Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING,60,
MLA：
Mingge Xia,et al."Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China".INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING 60.(2023)
